Tagged with Patient

Hong Kong Professor Anne W.M. Lee, vice chairman of the Hong Kong Anti-Cancer Society, discusses the role of patient associations in driving change within healthcare systems. Professor Lee, could you perhaps start by sharing the current strategic priorities of the Hong Kong Anti-Cancer Society (HKACS)? As the biggest non-government organization (NGO) in…

Hong Kong K P Tsang, president of the Hong Kong Alliance for Rare Diseases (HKARD), shares the challenges faced by patients with rare diseases and their caregivers in Hong Kong, the areas of improvement when it comes to rare disease policy, the advocacy work that HKARD is undertaking, and his insights on…

Spain Alba Ancochea of FEDER, the association that groups together Spain’s 337 rare disease patient organizations, explains how it interacts with both government and industry to the benefit of rare disease patients, the evolving situation for these patients in Spain, and her strategy for the future. Could you please start by…

Spain Antonio Bernal, president of the General Patient Alliance (AGP), discusses the role of the patient voice in the Spanish healthcare system and how the alliance is the bridge between the patient associations and the administration. Furthermore, he highlights the evolution of the Alliance and how the strength of the patients…

Spain Enrique Sánchez de León, president of Fundamed, discusses the role of the voice of the patients, and how they work alongside the General Patient Alliance to strengthen this voice. Furthermore, he highlights the importance of the Fundamed awards as a way to give back to those committed to the healthcare…

Portugal Quilaban, a Portuguese healthcare solutions company located in the Sintra business district of West Lisbon, has been led by Sérgio Luciano for five years. Luciano provides an insightful vision into the future of the healthcare system in Portugal, with reference to automation, international expansion and the significance of putting the…

UK Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by 2022. However, despite possessing the innovators, the infrastructure and the coverage, the UK’s thriving vaccine industry risks being blown off…

India Luca Visini, the recently appointed managing director of Eli Lilly & Company for India, shares with us his first perspective of the Indian ecosystem He also provides insights into some of his key objectives in India, which include consolidating the reputation of Eli Lilly as a key stakeholder in the…

Spain Santiago de Quiroga, president editor of leading Spanish pharmaceutical industry newspaper El Global and CEO of healthcare communications group WeCare-u, discusses the country’s health priorities, highlighting the upcoming Personalized Medicine Plan that the government will issue by the end of 2018 and predicts how regulators are going to find new…

Spain Ángel Luis Rodríguez de la Cuerda, secretary general of AESEG, the trade association of generic producers in Spain, discusses the initiatives that the organization is undertaking to develop a true generic culture in the country and a new proposal changing the requirement for originator drugs to remain at the same…

UK Lord O’Shaughnessy, parliamentary under secretary of state for health in the UK, discusses how stakeholders are interacting to ensure that the UK remains at the forefront of the global life sciences industry post-Brexit.    We have scrutinized the Life Sciences Industrial Strategy and found it to be a very optimistic…

India A strong supporter of public-private partnerships, MSD’s managing director in India, Vivek Kamath, explains how the company’s collaborative approach is the key to enhancing their reputation, improving patient outcomes and tackling unmet medical needs in India.   Mr. Kamath, you have worked for MSD for over four years and you…